Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go:
Stretch
investment:
Withheld
Arca have introduced new tools for property risk management and created a marketplace to trade portfolio risks to match buyers and sellers of financial products connected to the performance of real estate. They are opening up the concept of short term property market risk management for property portfolio managers.
days to go:
Expired
investment:
£575,000
PopUp Painting (PUP) is an art company that aims to be the leader in organising experiential social painting events in the UK. The company endeavours to bring art out of the classroom and gallery into the places people meet on an everyday basis, thereby, unleashing creativity. PUP has hosted over 45,000 guests to date. Total revenues to date are £1.1 million. In the last financial year, the company generated revenues of £373,000. The COVID-19 pandemic in March led to PUP launching its online art sessions which was met with positive feedback. The company resumed hosting in-person COVID-secure events from July 2020 onwards. PUP is seeking £175,000 at a pre-money valuation of £1.3 million to launch its own Central London experiential events space and to expand its current services to reach a new product market.
days to go:
Expired
investment:
Withheld
A medical condition management platform allowing clinicians to create their own app to improve a patient's health whilst reducing costs. Living With develops smart apps specific to a person's condition, they currently have 3 products with another in the development stage. Their primary app, Squeezy, is the top paid medical app in the UK that helps patients with their pelvic floor exercises. Other apps, allow clinicians to monitor a patient's bowel and bladder health, as well as those with rheumatoid arthritis. These apps are already in use at multiple NHS Trusts and clinics.
Funds are being raised to complete development of their apps to help those with lupus and lung cancer, in addition to further developing their existing products. The company aims to have thousands of apps that will be available worldwide to provide self-service treatment at any time. Living With is expecting to earn £1.07m in revenue by the end of March 2019.
days to go:
Expired
investment:
£250,000
The Landsite is the UK's first online property portal that connects various entities within the property industry such as developers, legal services, insurance advisors and architects, to one another, simplifying the process of finding and buying a property. By registering with The Landsite, a business/professional can list their business as operating in a specific region of the country and appear against all property searches that take place in that same region. The user then needs to put in their postcode or address and can then access properties within that region, as well as, seek available professional guidance to zero in upon a potential purchase. The platform also has an insights page that aims to become a recruitment, training and educational hub for the property industry. The company will use the investment to grow its business across different verticals.
days to go:
Expired
investment:
Withheld
Ablatus Therapeutics is a MedTech company developing a one-of-a-kind tissue ablation platform known as Bimodal Electric Tissue Ablation (BETA). This technology has been designed to overcome the limitations of existing products by offering ablation solutions in oncology (tumours) as well as non-oncology targets. With the proceeds, the company will finish the final elements of engineering of the generator and probe. It will also deliver formal safety test data that is a prerequisite for subsequent clinical trials.
days to go:
Expired
investment:
Withheld
Living With is a health technology company offering a pocket-friendly and simple patient management application that allows medical professionals treat and track patients remotely. The app aims to revolutionise the way doctors and hospitals access digital tools to treat patients while collecting data for medical device and pharma companies. The company owns Squeezy (a popular paid medical app in the UK) and already has five products in 17 NHS Trusts. Living With also has a contract with one of the world’s greatest medical device companies. Living With will use the proceeds to give 5 data (drug/device) and 50 access customers (clinic/doctor), become HIPAA compliant for the US and to quicken sales and marketing.
days to go:
Expired
investment:
£200,000
AgPlus has created a diagnostic platform for detecting human diseases and delivering laboratory instrument results instantly, whilst keeping in mind the business requirements and unmet requirements. The company works in collaboration with leading diagnostics companies to improve and share products quickly and globally. It aims is to become known as a leader in Point of Care diagnosis.
days to go:
Expired
investment:
£65,004
Carocell Bio is an early-stage Research and Design (R&D) company aiming to develop nanoparticle-based, novel peptide anti-inflammatories to treat atopic dermatitis/eczema (AD) and other serious inflammatory diseases. It argues that millions of people continue to be affected by debilitating skin ailments, which in turn, escalates the development of new pharmaceutical drugs. The company asserts that the anti-inflammatory therapeutics market will reach US$122.6 billion by 2025 from US$95.9 billion in 2019. The company aims to be a major contender in this market. Carocell Bio has also been awarded an Innovate UK grant of £390,874. The company is seeking £1 million in equity investment over the next 12 months to show that their compounds work in human tissue biopsies of several inflammatory diseases.
days to go:
Expired
investment:
Withheld
The world's first automated suturing tools for safe closure of standard and endoscopic wounds. Sutrue have already patented their devices and use industry-standard needles to offer clinical quality with improved speed and accuracy at the touch of a button. Needles are held in disposable cartridges as a safety feature to prevent injury when piercing skin with contaminated needles. This protects staff both during and after surgery for those working in medical and veterinary environments.
Sutrue is raising finance for the production process of their equipment, as well as applying for CE regulation via medical evaluations to receive approval to deploy their products in human and animal surgeries.
days to go:
Expired
investment:
Withheld
